SKYE Skye Bioscience, Inc.

CIK 0001516551 50 ready 8-Ks latest August 24, 2026, 4:02 PM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing August 24, 2026, 4:02 PM ET

Top materiality 1.00

Event mix other_material ×22 · leadership ×9 · m_and_a ×6

Sentiment 13 pos · 7 neg · 30 neu

Latest earnings reported 2025-Q2

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for SKYE

Highest-materiality recent filing

Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company

August 14, 2026, 9:36 AM ET M&A materiality 1.00 neutral item 1.01 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change ×2

Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
Post-close ownership: Redx shareholders ~46.17%, Skye ~5.38%, new investors ~48.45% (assuming $67.9M concurrent financing).

Read filing →

August 24, 2026, 4:02 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01

Skye Bioscience enters $22M ELOC with Redmile; warrant for $5M shares

ELOC facility up to $22M for common/non-voting common stock; $2M/month cap over 3-year term, pricing at lesser of PIPE price or Market Price (floor 90% of PIPE price).
August 18, 2026, 7:56 PM ET regulatory materiality 0.85 negative item 3.01

Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity

Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.
August 14, 2026, 9:36 AM ET M&A materiality 1.00 neutral item 1.01 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change ×2

Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company

Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
June 22, 2026, 5:53 PM ET other material materiality 0.65 negative item 8.01

Skye Bioscience transfers Nasdaq listing to Capital Market after equity deficiency; bid price non-compliance continues

Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.
May 29, 2026, 4:54 PM ET other material materiality 0.70 neutral item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M

Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.
May 15, 2026, 4:00 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity

Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.
April 3, 2026, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 9.01

Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150

John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
March 19, 2026, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00

Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
March 10, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks

Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
February 2, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed

Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
December 23, 2025, 6:59 PM ET other material materiality 0.65 positive item 1.01 ◈ Material Agreements

Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab

Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
November 10, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M

Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
October 6, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 9.01

Skye Bioscience Reports Phase 2a Data: Nimacimab Monotherapy Misses Endpoint, Combination Shows Added Weight Loss

Nimacimab monotherapy at 200 mg failed primary endpoint with placebo-subtracted weight loss of -1.26% (p=0.2699, mITT).
August 7, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025

Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
March 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025

Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025

Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
September 4, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options

Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.
July 3, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1

Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.
June 10, 2024, 7:59 PM ET other material materiality 0.85 negative item 8.01 item 9.01

Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program

Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
April 3, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Skye Bioscience reports pro forma equity >$5M after $90M private placement

Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
March 13, 2024, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements ×3

Skye Bioscience raises $40M via PIPE of 4M shares at $10 each

Issued 4,000,000 shares at $10.00 per share for gross proceeds of $40,000,000.
March 4, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1

Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
February 12, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance

Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
January 29, 2024, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial

Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.
December 5, 2023, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 1.02 item 7.01 item 9.01 ◈ Material Agreements ×3

Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab

Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.
October 3, 2023, 7:59 PM ET other material materiality 0.70 neutral item 5.02 item 8.01 item 9.01

Skye Bioscience increases authorized common shares from 20M to 100M and expands equity incentive pool

Board and majority stockholders approved incentive plan amendment raising authorized shares to 1,846,883, with automatic 5% annual increases from 2024-2032.
September 7, 2023, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Skye Bioscience announces 1-for-250 reverse stock split effective Sept 8, 2023

Reverse split at 1:250 reduces outstanding shares from ~3.078B to ~12.3M.
September 1, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Skye Bioscience appoints Schwab and Grayson to board; Grayson gets $350k bonus and large performance RSUs

Paul Grayson appointed director with a $350,000 sign-on bonus.
August 21, 2023, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2◈ M&A Transactions

Skye Bioscience acquires Bird Rock Bio in $17M financing, gains Phase 2 CB1 antibody nimacimab

Acquired Bird Rock Bio; lead asset nimacimab is a phase 2-ready peripherally-restricted CB1 inhibitor for glaucoma and CKD.
February 23, 2023, 6:59 PM ET other material materiality 0.80 neutral item 1.01 item 1.02 item 3.02 item 9.01 ◈ Material Agreements ×2

Skye Bioscience enters master transaction agreement with major shareholder to convert debt and exercise warrants

Emerald Health Sciences exercised 16,641,486 warrants for $282,905, paid by reducing Skye's debt under the Credit Agreement.
February 15, 2023, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 2.01 item 8.01 item 9.01 ◈ M&A Transactions◈ Material Agreements

Skye Bioscience closes sale of Verdélite Sciences for $9.48M; receives $5.60M cash at closing

Sold wholly owned subsidiary Verdélite Sciences and 88k sq ft cannabis facility in St-Eustache, Quebec to C3 Souvenir Holding.
January 27, 2023, 6:59 PM ET litigation materiality 0.75 negative item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Skye Bioscience faces $4.85M jury verdict in wrongful termination case; amends Verdeilite sale terms

Jury awards Wendy Cunning $512,500 economic, $840,960 non-economic, and $3.5M punitive damages; company plans to appeal.
November 23, 2022, 6:59 PM ET debt materiality 0.70 negative item 1.01 item 3.03 item 9.01 ◈ Material Agreements

Skye Bioscience prepays $945K debt, extends maturity, reprices warrants to $0.017

Prepaid $944,862 of principal and interest; remaining convertible debt of $1.848M.
October 19, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 2.03 item 9.01

Skye extends EHT deal outside date to Nov 15, receives $700K loan from EHT

Third Amendment extends outside date for acquisition of Emerald Health Therapeutics to November 15, 2022, subject to possible 15-day extension.
October 3, 2022, 7:59 PM ET M&A materiality 0.85 positive item 4.01 item 5.07 item 7.01 item 9.01

Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent

97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.
June 17, 2022, 7:59 PM ET M&A materiality 0.80 neutral item 1.01 item 4.01 item 5.02 item 9.01

Skye Bioscience amends arrangement agreement with Emerald Health Therapeutics, appoints new board and changes auditor

Filed amendment to Arrangement Agreement with Emerald Health Therapeutics waiving closing conditions and revising post-closing board.

Executive changes

Departed

Tu Diep

Other Named Officer

SKYE · Skye Bioscience, Inc.

Effective: 2027-01-31
Filed: August 14, 2026, 9:36 AM ET

Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027

Departed

Punit Dhillon

Other Named Officer

SKYE · Skye Bioscience, Inc.

Effective: 2027-08-31
Filed: August 14, 2026, 9:36 AM ET

Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027

Appointed

Puneet S. Arora

Chief Medical Officer

SKYE · Skye Bioscience, Inc.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

On September 3, 2024, Skye Bioscience, Inc. (the “Company”) announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer, effective as of September 3, 2024 (the “Effective Date”).

Departed

Keith Ward, PhD

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-08-01
Filed: July 3, 2024, 7:59 PM ET

On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.

Appointed

Karen L. Smith MD, PhD, MBA, LLM

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-07-02
Filed: July 3, 2024, 7:59 PM ET

the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.

Departed

Praveen Tyle, PhD

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-08-01
Filed: July 3, 2024, 7:59 PM ET

On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.

Departed

Margaret Dalesandro

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-08-01
Filed: March 4, 2024, 6:59 PM ET

Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.

Appointed

Annalisa Jenkins

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-02-29
Filed: March 4, 2024, 6:59 PM ET

appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.

Appointed

Andrew Schwab

Director

SKYE · Skye Bioscience, Inc.

Filed: September 1, 2023, 7:59 PM ET

Andrew Schwab and Paul Grayson were appointed to the Board.

Appointed

Paul Grayson

Director

SKYE · Skye Bioscience, Inc.

Filed: September 1, 2023, 7:59 PM ET

Andrew Schwab and Paul Grayson were appointed to the Board.

Appointed

Andrew Schwab

Director

SKYE · Skye Bioscience, Inc.

Effective: 2023-08-21
Filed: August 21, 2023, 7:59 PM ET

In accordance with the closing of the Merger, Andrew Schwab and Paul Grayson were appointed to the Board.

Appointed

Paul Grayson

Director

SKYE · Skye Bioscience, Inc.

Effective: 2023-08-21
Filed: August 21, 2023, 7:59 PM ET

In accordance with the closing of the Merger, Andrew Schwab and Paul Grayson were appointed to the Board.

Earnings & guidance

2025-Q2 EPS reported -$0.72 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

13 positive 7 negative 30 neutral

source · SKYE on sec.gov